TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06668038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary and multicenter validation of re-irradiation with curative intent
Description: Validation in multidisciplinary and multicenter meeting of re-irradiation indication after review of technical data (images, structures and doses) of 1st irradiation and recent diagnosis images of the lesion to be irradiated, merged using MIM.~In case of re-irradiation validation, validation in multidisciplinary and multicenter meeting of cumulated doses after review of EQD2 doses summation using MIM.
Study: NCT06667518

Intervention type: DEVICE
Intervention: Neuromuscular Activity Assessment
Description: K-Pull dynamometer is an assessment tool used to quantify muscle strength. It uses traction through a non-elastic strap to facilitate isometric contractions.~K-Myo (non-invasive EMG sensor) is an assessment tool used to detect muscle activation and tracking patient's improvement.
Study: NCT06665854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Song Group
Description: The rhythmic song group will first click on the start button on the mobile application. When starting the application to stimulate the baby, a bell will ring, and the baby movements will be coded as present/absent via the mobile application; then they will sing a rhythmic song and recode the baby movements as present/absent via the mobile application. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Instrument Group
Description: The Rhythmic Instrument Group will first click on the start button on the mobile application. Then, they will ring a bell to start the application to warn the baby, and they will code the baby's movements as present/absent via the mobile application; then they will play a rhythmic instrument and code the baby's movements as present/absent via the mobile application again. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Control Group will first code Start via the mobile application. Then, a bell will ring to warn the baby, they will code the baby's movements as present/absent via the mobile application again and will only rest. When the application is over, all pregnant women will code Finish via the mobile application. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.
Study: NCT06667050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus sintilimab and bevacizumab
Description: Laparoscopic exploration should be performed to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum.~3 cycles of neoadjuvant therapy will be administered: capecitabine: 100 mg/m2, Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; sintilimab: 200 mg, iv drip, d1, bevacizumab biosimilar (IBI305) 10mg~/Kg, iv drip, d1, q3w. Radical D2 gastric cancer resection will be performed within 6-8 weeks after the last administration of chemotherapy plus sintilimab and bevacizumab biosimilar (IBI305).~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with CAPOX regimen for up to 3 cycles.
Study: NCT06668766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10-cm Single Lumen Mildine
Description: Arm Description: The BD Powerglide Pro Midline catheter is currently approved for use by the FDA and by Albany Medical Center. This 18-gauge or 20-guage MC is distinct in that it is a standard 10-cm, does not require premeasurement or trimming of the catheter prior to placement, and features an accelerated Seldinger technique, meaning that it has a built-in deployable internal wire system. Additionally, because it is only 10-cm, it does not require a confirmatory chest x-ray prior to use. The provider will use standard aseptic technique for placing the MC (e.g., chlorhexidine prep, sterile probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number from the randomization packet to allow for vessel depth and size measurement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4.78 cm Long Peripheral Intravenous Catheter
Description: The BD Insyte Autoguard 4.78 cm 18- or 20-gauge needle with self-retraction is currently approved for use by the FDA and by Albany Medical center. The long PIV will be placed using standard aseptic technique (e.g., chlorhexidine prep, sterile gloves, sterile ultrasound probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number in the comments section of the QPATH worksheet to allow for vessel depth and size measurement. Operators will be instructed to use standard techniques in US-guided vascular access.
Study: NCT06666062

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: implant placement and low level laser therapy
Description: Laser biomodulation with low level laser therapy around delayed implant

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: implant placement
Description: Delayed implant placement restoring missed tooth
Study: NCT05498428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously by manual injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously by manual injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously by manual injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered as an oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered as an oral tablet.
Study: NCT06666322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: 2022 WHO First Line Induction Therapy:~1. Liposomal Amphotericin B 10mg/kg IV given once~2. Flucytosine 100mg/kg/day for 14 days in divided doses~3. Fluconazole 1200mg/day for 14 days Consolidation Therapy: Fluconazole 800mg/day from 2 to 10 weeks Secondary Prophylaxis: Fluconazole 200mg/day through 1 year minimum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oteseconazole - antifungal therapy 1
Description: Oteseconazole, is an azole metalloenzyme inhibitor targeting the fungal sterol, 14α demethylase (CYP51)~* Loading doses of oral Oteseconazole 600 mg twice daily for 10 days, then 600 mg oteseconazole weekly on weeks 3, 4, 5, and 6.~* Liposomal Amphotericin B 10 mg/kg IV once.~* No fluconazole or 5FC to be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sfu-AM2-19 Injection - antifungal therapy 2
Description: Ambisome 10 mg/kg IV administered once Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 1.5 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days OR SF001 2.0 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antifungal therapy 3
Description: To be determined

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antifungal therapy 4
Description: To be determined
Study: NCT06667258

Intervention type: DEVICE
Intervention: Ear ECG/PPG sensors
Description: Medical graded electrodes placed in the mastoid, in-ear foam-based earpiece (like commercial earplugs) with cloth electrodes, off-the-shelf pulse oximeter placed behind the ear

Intervention type: DEVICE
Intervention: Ear ECG/PPG sensors
Description: Medical graded electrodes placed in the mastoid, in-ear foam-based earpiece (like commercial earplugs) with cloth electrodes, off-the-shelf pulse oximeter placed behind the ear
Study: NCT06619314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral Tablet
Study: NCT05498428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered as an oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered as an oral tablet.
Study: NCT03614351

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein (PROT)
Description: Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (CONT)
Description: Instructed not to alter their diet based on the app, and to continue to eat as they normally would.
Study: NCT05181891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Incentives for submitting negative-alcohol urine samples
Study: NCT05498428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administrated by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administrated by IV infusion.
Study: NCT06619314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral Tablet
Study: NCT05498428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administrated by IV infusion.
Study: NCT05498428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administrated by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulant (DOAC)
Description: DOAC will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Description: LMWH will be administered subcutaneously.
Study: NCT06201689

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Placebo Control Form 1
Description: Participants will use their Radicle Energy Placebo Control Form 1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Active Study Product 1.1 Usage
Description: Participants will use their Radicle Energy Active Study Product 1.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Active Study Product 1.2 Usage
Description: Participants will use their Radicle Energy Active Study Product 1.2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Placebo Control Form 2
Description: Participants will use their Radicle Energy Placebo Control Form 2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Active Study Product 2.1 Usage
Description: Participants will use their Radicle Energy Active Study Product 2.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Placebo Control Form 3
Description: Participants will use their Radicle Energy Placebo Control Form 3 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Active Study Product 3.1 Usage
Description: Participants will use their Radicle Energy Active Study Product 3.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Placebo Control Form 4
Description: Participants will use their Radicle Energy Placebo Control Form 4 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Active Study Product 4.1 Usage
Description: Participants will use their Radicle Energy Active Study Product 4.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Active Study Product 4.2 Usage
Description: Participants will use their Radicle Energy Active Study Product 4.2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Active Study Product 4.3 Usage
Description: Participants will use their Radicle Energy Active Study Product 4.3 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Placebo Control Form 5.1.0
Description: Participants will use their Radicle Energy Placebo Control Form 5.0 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Active Study Product 5.1.1 Usage
Description: Participants will use their Radicle Energy Active Study Product 5.1.1 as directed for a period of 6 weeks.
Study: NCT06619314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: Oral Capsule
Study: NCT06682260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Infusion of intravenous nitroglycerin beginning at 2 microgram/kg/min (2 ml/hour) and titrated with the aim of a MAP reduction of 20-30%. Infusion rate will not be increased after the first 30 minutes and is limited to 0.1 µg/kg/min to 5 µg/kg/min.
Study: NCT06682676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal ventilation function test and cold and dry air nasal provocation test
Description: The visual analogue scale (VAS) of nasal symptoms, rhinoconjunctivitis quality of life questionnaire (RQLQ), total nasal symptom score (TNSS), total nasal volume (TNV), minimum cross-sectional area (MCA), peak inspiratory flow (PNIF), and total nasal resistance (TNR) at 75Pa were recorded before and after nasal ventilation function test and CDA nasal provocation test.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal ventilation function test and cold and dry air nasal provocation test
Description: The visual analogue scale (VAS) of nasal symptoms, rhinoconjunctivitis quality of life questionnaire (RQLQ), total nasal symptom score (TNSS), total nasal volume (TNV), minimum cross-sectional area (MCA), peak inspiratory flow (PNIF), and total nasal resistance (TNR) at 75Pa were recorded before and after nasal ventilation function test and CDA nasal provocation test.
Study: NCT06682130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A：Patients with PR or ctDNA positivity after salvage treatment
Description: 1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group A: 2.5mg day8~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6; Patients in Group A who intend to receive Glofitamab+ASCT will receive Glofitamab 2.5mg on day8 and start ASCT pretreatment on day15.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B: Patients with CR and ctDNA negative after salvage treatment
Description: Group B patients initiated ASCT treatment directly after evaluating the efficacy of salvage treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group C: Patients with SD/PD after posterior treatment
Description: 1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group C: cycle1 2.5mg day8, 10mg day15 cycle2 30mg day21~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6;~After two treatment cycles with Glofitamab, patients in group C had a PET-CT to assess efficacy. Those with partial remission proceeded to ASCT consolidation, those with complete remission chose between ASCT or Glofitamab maintenance, and those with stable disease or progressive disease exited the trial.
Study: NCT05181891

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-contingent control
Description: Incentives for submitting urine samples
Study: NCT05966142

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19
Study: NCT06283563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity tracking
Description: At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in MS will be given. Participants in the intervention group will be asked to join one of two groups created by the researchers via messaging app. Reminders will be arranged on Monday-Wednesday-Thursday in one of the groups, and on Tuesday-Thursday-Saturday in the other group. In this regard, it will be emphasized that he/she should exercise at least 3 days a week. In this regard, they will be encouraged to walk for at least 30 minutes, 3 days a week, on the days they determine. The total intervention period will be 8 weeks. Reminders to exercise will be given by the researchers in the created messaging app group. Patients will be reminded to take their mobile phones with them during physical activity and to record their daily exercise minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No physical activity tracking
Description: At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in multiple sclerosis will be given. Participants will be encouraged to continue their routine lives and no reminders will be given.
Study: NCT06683937

Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file
Study: NCT06684015

Intervention type: DRUG
Intervention: İNTRATECHAL MORPHİNE GROUP
Description: Addition of intrathecal morphine as an adjuvant to local anesthesia in routine spinal anesthesia application and multimodal analgesia applications

Intervention type: PROCEDURE
Intervention: Erector Spinae Plane Block
Description: Application of erector spinae plane block and multimodal analgesia applications at the end of the operation after routine spinal anesthesia application
Study: NCT06683287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: red light and distant image screen
Description: red light plus distant image screen, children use these two devices at the same time

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: red light
Description: children use red light for 3 minutes each time, twice a day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: distant image screen
Description: Children in this group were asked to use this device for ≥1 hour/day
Study: NCT06683040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxacom
Description: Lyophilisate for solution for intravenous administration, 6.3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxacom
Description: Lyophilisate for solution for intravenous administration, 6.3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxacom
Description: Lyophilisate for solution for intravenous administration, 6.3 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study: NCT06684730

Intervention type: PROCEDURE
Intervention: Hand Function Assessment Scales
Description: The Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), The Box and Block Test (BBT) and Action Research Arm Test (ARAT) will be used as hand function assessment scales.

Intervention type: PROCEDURE
Intervention: Hand Function Assessment Scales
Description: The Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), The Box and Block Test (BBT) and Action Research Arm Test (ARAT) will be used as hand function assessment scales.

Intervention type: OTHER
Intervention: Prosthesis Satisfaction Scale
Description: The Quebec Assistive Technology User Satisfaction Assessment (Q-YTKMD) Questionnaire will be used.

Intervention type: OTHER
Intervention: Prosthesis Satisfaction Scale
Description: The Quebec Assistive Technology User Satisfaction Assessment (Q-YTKMD) Questionnaire will be used.

Intervention type: OTHER
Intervention: Quality of Life Scale
Description: 5Q-5D-5L will be used as quality of life scale.

Intervention type: OTHER
Intervention: Quality of Life Scale
Description: 5Q-5D-5L will be used as quality of life scale.
Study: NCT05980975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: 4th hour, 8th hour and 12th hour of after the surgery, the patients in the coffee group received 10 gr. granulated coffee.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water
Description: hot water group were given 200 ml of 50-60 C0 sugar-free hot water at the 4th hour, 8th hour and 12th hour of after the operation
Study: NCT05966142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decisions support
Description: Prescribing recommendations to the provider based on the pharmacogenetic testing results
Study: NCT06402721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Single oral dose.